Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:musician
|
| gptkbp:approves |
coronary artery disease
|
| gptkbp:clinical_trial |
gptkb:Abbott_Laboratories
Phase II multiple countries improved quality of life Phase III Phase I positive outcomes high success rate long-term efficacy enhanced patient satisfaction widespread adoption low complication rate favorable cost-effectiveness effective in elderly patients SPIRIT trials effective in men effective in patients with comorbidities effective in patients with multi-vessel disease effective in women increased usage in high-risk patients reduced angina symptoms |
| gptkbp:coat_of_arms |
gptkb:everolimus
|
| gptkbp:competitors |
Orsiro stent
Promus stent Resolute stent Synergy stent |
| gptkbp:complications |
thrombosis
|
| gptkbp:design |
thin strut technology
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xience V
|
| gptkbp:indication |
stenting of coronary arteries
|
| gptkbp:invention |
2026
patented |
| gptkbp:manufacturer |
gptkb:Abbott_Laboratories
|
| gptkbp:marketed_as |
gptkb:Europe
gptkb:Asia gptkb:United_States |
| gptkbp:provides_information_on |
ACC/ AHA guidelines
ESC guidelines |
| gptkbp:regulatory_compliance |
gptkb:CE_Mark
gptkb:FDA |
| gptkbp:release_year |
gptkb:2006
|
| gptkbp:side_effect |
gptkb:hospital
gptkb:cemetery allergic reaction bleeding complications stent thrombosis |
| gptkbp:successor |
gptkb:Xience_Xpedition
|
| gptkbp:treatment |
improved patient outcomes
long-term safety effective in complex lesions effective in diabetic patients lower target lesion revascularization rate reduced restenosis rate |
| gptkbp:type |
gptkb:hospital
|
| gptkbp:used_in |
percutaneous coronary intervention
|
| gptkbp:bfsParent |
gptkb:Xience_drug-eluting_stent
|
| gptkbp:bfsLayer |
7
|